IPO Year: 2025
Exchange: AMEX
| Date | Price Target | Rating | Analyst |
|---|
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
Fastest customizable press release news feed in the world
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. ("Inscobee") and Apimeds, Inc., ("Apimeds Korea") today announced that on March 20, 2026, Inscobee and Apimeds Korea, together with other stockholders of Apimeds Pharmaceuticals US, Inc. (the "Company") (NYSE:APUS) who beneficially own at least 66 2/3% of the voting power of the Company, delivered an action by written consent of the stockholders to the Company (the "Written Consent") to remove Elona Kogan, Jakap Koo, Carol O'Donnell and Dr. Bennett Weintraub as directors of the board of directors of the Company, effective immediately. In addition, pursuant to the Written
MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE:APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, "Inscobee"), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect a hostile takeover of the Company's Board of Directors by written consent. Inscobee claims to have removed all four sitting directors of APUS and installed three hand-picked replacements without notice to the Company, without authorization from the Company as
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026. The scheduled interaction follows the recent submission of a Type C meeting request and represents an important step in the coordinated U.S. regulatory strategy for LT-100. The meeting is intended to support alignment with the FDA on key development
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds Pharmaceuticals US Inc. (NYSE:APUS) and Mindwave Innovations Inc. The merger brings together a biotech development platform with an AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment, for which E.F. Hutton acted as Placement Agent. E.F. Hutton's involvement underscores its commitment to advancing the combined company's strategic growth across late-stage biotech development and institutional Digital Asset Treasury Solutions. E.F. Hutton worked closely with both companies to shape the transaction fram
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company's financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones. The financing also facilitates the integration of MindWave Innovations Inc., aligning corporate operations and financial management processes. As part of that integration, approximately 1,000 Bitcoin previously held by MindWave have been transferred into a segregated, risk-managed structure. This digital-asset position is governed under a defined inv
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury, digital asset yield generation, and $NILA-powered ecosystem. The combined company integrates high-growth biotechnology and institutional digital-treasury capabilities, with the merger supported by a simultaneous PIPE of up to $100 million to advance Apimeds' clinical programs and expand MindWave's digital asset infrastructure. (NYSE:APUS) Apimeds Pharmaceuticals US, Inc. ("Apimeds"), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that i
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem. The ai² Futures Lab™ functions as both a discovery engine for potential therapeutic assets and a training ground for the next generation of biotech and business leaders. Through this collaboration, University of Idaho students will work
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon's Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem. ai² Futures Lab functions as both a discovery engine for potential therapeutic assets and a training ground for tomorrow's industry leaders. Through this collaboration, University of Oregon students will engage directly with Apime
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego's Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry. Future Labs is part of Apimeds' ai² innovation platform, connecting university students with real-world strategy and business development projects. Through this collaboration, student teams will work closely with Apimeds mentors to identify and evaluate opportunities to advance developm
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today welcomed the U.S. Food and Drug Administration's (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company's lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled "Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry", can be found here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-chronic-pain. Erik Emerson, Chief Executive Officer of Apimeds, issued the following statement: "The FDA's draft guidance represents a landmark moment for comp
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)
8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
SCHEDULE 13G - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)
PREM14C - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Live Leadership Updates
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. ("Inscobee") and Apimeds, Inc., ("Apimeds Korea") today announced that on March 20, 2026, Inscobee and Apimeds Korea, together with other stockholders of Apimeds Pharmaceuticals US, Inc. (the "Company") (NYSE:APUS) who beneficially own at least 66 2/3% of the voting power of the Company, delivered an action by written consent of the stockholders to the Company (the "Written Consent") to remove Elona Kogan, Jakap Koo, Carol O'Donnell and Dr. Bennett Weintraub as directors of the board of directors of the Company, effective immediately. In addition, pursuant to the Written